Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of YL-15293 in Advanced Solid Tumors with KRAS Mutation
NCT05173805Phase 2Unknown
- Sponsor
- Yingli Pharma
- Start
- Jan 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of YL-15293 in solid tumor, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC), sponsored by Yingli Pharma. Primary endpoints: Overall Response Rate at 2 years, Progression-Free Survival at 2 years and 2 more. Status: unknown.
02
Drugs
YL-15293
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05173805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05173805.